Enavate Launches With $300m To Help Drug Developers Get Over Funding Hurdles

Patient Square Is Sole Initial Investor

The firm, helmed by former life science investment banker James Boylan, views the current difficult financial market as the perfect time to offer its expertise and capital to growing companies.

Businessman jumping on chart columns
Growing companies face a chilly market, which is where Enevate hopes to step in • Source: Alamy

Health care investment firm Patient Square Capital launched a new portfolio company on 2 May called Enavate Sciences, which itself is an investor with $300m that it will use to back therapeutic and enabling technology companies in growth mode. Former life science investment banker and current Enavate CEO James Boylan said now, when many biopharmaceutical firms are running into trouble raising cash, is the right time to launch this new venture.

Boylan most recently served as president and head of investment banking at SVB Leerink, where he led the transformation of the health care investment bank Leerink Swann after its acquisition by SVB Financial in 2019. (Also see "Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services" - Scrip, 16 November, 2018

More from Financing

More from Business